Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Systematic Review
  • Published:

Efficacy and safety of macrolides in the treatment of children with bronchiectasis: a meta-analysis

Pediatric Research volume 94, pages 1600–1608 (2023)Cite this article

Abstract

Background

This study summarized the available randomized controlled trials (RCTs) to assess the efficacy and safety of macrolides on pathogens, lung function, laboratory parameters, and safety in children with bronchiectasis.

Methods

PubMed, EMBASE, and the Cochrane Library were searched for available papers published up to June 2021. The outcomes were the pathogens, adverse events (AEs), and the forced expiratory volume in one second (FEV1%) predicted.

Results

Seven RCTs (633 participants) were included. The long-term use of macrolides reduced the risk of the presence of Moraxella catarrhalis (RR = 0.67, 95% CI: 0.30–1.50, P = 0.001; I2 = 0.0%, Pheterogeneity = 0.433), but not Haemophilus influenza (RR = 0.19, 95% CI: 0.08–0.49, P = 0.333; I2 = 57.0%, Pheterogeneity = 0.040), Streptococcus pneumonia (RR = 0.91, 95% CI: 0.61–1.35, P = 0.635; I2 = 0.0%, Pheterogeneity = 0.515), Staphylococcus aureus (RR = 1.01, 95% CI: 0.36–2.84, P = 0.986; I2 = 61.9%, Pheterogeneity = 0.033), and any pathogens present (RR = 0.61, 95% CI: 0.29–1.29, P = 0.195; I2 = 80.3%, Pheterogeneity = 0.006). Long-term macrolides had no effect on FEV1% predicted (WMD = 2.61, 95% CI: –1.31, 6.53, P = 0.192; I2 = 0.0%, Pheterogeneity = 0.896). Long-term macrolides did not increase the risk of AEs or serious AEs.

Conclusion

Macrolides do not significantly reduce the risk of pathogens present (except for Moraxella catarrhalis) or increase FEV1% predicted among children with bronchiectasis. Moreover, macrolides were not associated with AEs. Considering the limitations of the meta-analysis, further larger-scale RCTs are needed to confirm the findings.

Impact

  • Macrolides do not significantly reduce the risk of pathogens present (except for Moraxella catarrhalis) among children with bronchiectasis.

  • Macrolides do not significantly increase FEV1% predicted among children with bronchiectasis.

  • This meta-analysis reports on the efficacy and safety of macrolides in the treatment of children with bronchiectasis, providing evidence for the management of children with bronchiectasis.

  • This meta-analysis does not support the use of macrolides in the management of children with bronchiectasis unless the presence of Moraxella catarrhalis is provenor suspected.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Study selection process.
Fig. 2: Forest plot showing the effect of macrolides on pathogens.
Fig. 3: Forest plot showing the effect of macrolides on FEV1% predicted.
Fig. 4: Forest plot showing the outcomes of macrolides.
Fig. 5: Forest plot showing the other outcomes.
Fig. 6: Sensitivity analysis of the pathogens.

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this published article.

References

  1. Goyal, V., Grimwood, K., Marchant, J., Masters, I. B. & Chang, A. B. Pediatric bronchiectasis: no longer an orphan disease. Pediatr. Pulmonol. 51, 450–469 (2016).

    Article  PubMed  Google Scholar 

  2. McCallum, G. B. & Binks, M. J. The epidemiology of chronic suppurative lung disease and bronchiectasis in children and adolescents. Front. Pediatr. 5, 27 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pasteur, M. C., Bilton, D. & Hill, A. T. British Thoracic Society Non-CF Bronchiectasis Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65(Suppl 1), i1–i58 (2010).

    Article  PubMed  Google Scholar 

  4. McShane, P. J., Naureckas, E. T., Tino, G. & Strek, M. E. Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 188, 647–656 (2013).

    Article  PubMed  Google Scholar 

  5. El Boustany, P. et al. A review of non-cystic fibrosis bronchiectasis in children with a focus on the role of long-term treatment with macrolides. Pediatr. Pulmonol. 54, 487–496 (2019).

    Article  PubMed  Google Scholar 

  6. Twiss, J., Metcalfe, R., Edwards, E. & Byrnes, C. New Zealand national incidence of bronchiectasis “too high” for a developed country. Arch. Dis. Child 90, 737–740 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Das, L. & Kovesi, T. A. Bronchiectasis in children from Qikiqtani (Baffin) Region, Nunavut, Canada. Ann. Am. Thorac. Soc. 12, 96–100 (2015).

    Article  PubMed  Google Scholar 

  8. Kapur, N., Masters, I. B., Newcombe, P. & Chang, A. B. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest 141, 1018–1024 (2012).

    Article  PubMed  Google Scholar 

  9. Munro, K. A. et al. Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression? Pediatr. Pulmonol. 46, 131–138 (2011).

    Article  PubMed  Google Scholar 

  10. Kapur, N., Masters, I. B. & Chang, A. B. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability? Chest 138, 158–164 (2010).

    Article  PubMed  Google Scholar 

  11. Hill, A. T. et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax 74, 1–69 (2019).

    PubMed  Google Scholar 

  12. Khoo, J. K., Venning, V., Wong, C. & Jayaram, L. Bronchiectasis in the last five years: new developments. J. Clin. Med. 5, 115 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Haworth, C. S., Bilton, D. & Elborn, J. S. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir. Med. 108, 1397–1408 (2014).

    Article  PubMed  Google Scholar 

  14. Steel, H. C., Theron, A. J., Cockeran, R., Anderson, R. & Feldman, C. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012, 584262 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Smith, D. et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax 75, 370–404 (2020).

    Article  PubMed  Google Scholar 

  16. Polverino, E. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 50, 1700629 (2017).

    Article  PubMed  Google Scholar 

  17. Chang, A. B. et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur. Respir. J. 58, 2002990 (2021).

    Article  CAS  PubMed  Google Scholar 

  18. Chang, A. B. et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med. J. Aust. 202, 21–23 (2015).

    Article  PubMed  Google Scholar 

  19. Chalmers, J. D. et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir. Med. 7, 845–854 (2019).

    Article  CAS  PubMed  Google Scholar 

  20. Wang, D., Fu, W. & Dai, J. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis. Medicine (Baltimore) 98, e15285 (2019).

    Article  CAS  PubMed  Google Scholar 

  21. Kelly, C. et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst. Rev. 3, CD012406 (2018).

    PubMed  Google Scholar 

  22. PRISMA 2020. J. Clin. Epidemiol. 134, A5–A6 (2021).

  23. Swartz, M. K. PRISMA 2020: an Update. J. Pediatr. Health Care 35, 351 (2021).

    Article  PubMed  Google Scholar 

  24. Aslam, S. & Emmanuel, P. Formulating a researchable question: a critical step for facilitating good clinical research. Indian J. Sex. Transm. Dis. AIDS 31, 47–50 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).

    Article  PubMed  Google Scholar 

  26. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557–560 (2003).

    Article  PubMed  PubMed Central  Google Scholar 

  27. Higgins, J. P. T. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (Cochrane Collaboration, London, 2020).

  28. Goyal, V. et al. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 392, 1197–1206 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Goyal, V. et al. Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial. Lancet Respir. Med. 7, 791–801 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hare, K. M. et al. Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo. Eur. J. Clin. Microbiol. Infect. Dis. 34, 2275–2285 (2015).

    Article  CAS  PubMed  Google Scholar 

  31. Valery, P. C. et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. lancet Respir. Med. 1, 610–620 (2013).

    Article  CAS  PubMed  Google Scholar 

  32. Koh, Y. Y., Lee, M. H., Sun, Y. H., Sung, K. W. & Chae, J. H. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur. Respir. J. 10, 994–999 (1997).

    Article  CAS  PubMed  Google Scholar 

  33. Masekela, R. et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV related bronchiectasis: a randomised, placebo-controlled trial. J. Antivir. Antiretrovir. 5, 044–049 (2013).

    CAS  Google Scholar 

  34. Yalçin, E. et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J. Clin. Pharm. Ther. 31, 49–55 (2006).

    Article  PubMed  Google Scholar 

  35. Ramsey, K. A. & Schultz, A. Monitoring disease progression in childhood bronchiectasis. Front. Pediatr. 10, 1010016 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  36. McDonnell, M. J., Ward, C., Lordan, J. L. & Rutherford, R. M. Non-cystic fibrosis bronchiectasis. QJM 106, 709–715 (2013).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric, The First Affiliated Hospital of Henan University of TCM, 19 Renmin Road, Jinshui District, 450000, Zhengzhou, China

    Guihua Song, Yan Zhang, Suping Yu, Mengmeng Sun, Bingxue Zhang, Minghao Peng, Weigang Lv & Hongyun Zhou

Authors
  1. Guihua Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suping Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mengmeng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bingxue Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Minghao Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weigang Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hongyun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: G.S. Data curation: M.P., W.L. Formal analysis: M.S., B.Z. Methodology: G.S., S.Y. Writing—original draft: G.S., Y.Z. Writing—review and editing: H.Z.

Corresponding author

Correspondence to Guihua Song.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, G., Zhang, Y., Yu, S. et al. Efficacy and safety of macrolides in the treatment of children with bronchiectasis: a meta-analysis. Pediatr Res 94, 1600–1608 (2023). https://doi.org/10.1038/s41390-023-02591-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41390-023-02591-5

This article is cited by

Search

Advanced search

Quick links